Mechanism and application of serum amyloid A in clinical diseases

doi:10.3969/j.issn.1673-8640.2021.07.017

Abstract

Abstract:

Serum amyloid A（SAA） is an acute phase-reactive protein that rapidly increases in the acute phase of infection,inflammation and tissue damage,and rapidly declines during the recovery phase of the diseases. There are important links between SAA and infection caused by bacteria or viruses,atherosclerosis,tumors,transplant rejection,rheumatoid,amyloidosis and so on. This review focuses on the structure,function and determination method of the SAA superfamily and the development of mechanisms and applications of SAA and clinical diseases.

Key words: Serum amyloid A, Infection, Coronary heart disease, Tumor, Inflammation

CLC Number:

R446.1

LIU Jinyan, ZHAO Juntao, XIANG Mingjie. Mechanism and application of serum amyloid A in clinical diseases[J]. Laboratory Medicine, 2021, 36(7): 756-760.

References 43

[1]	SHRIDAS P, DE BEER M C, WEBB N R. High-density lipoprotein inhibits serum amyloid A-mediated reactive-oxygen species generation and NLRP3 inflammasome activation[J]. J Biol Chem, 2018, 293(34):13257-13269. DOI URL
[2]	DE BUCK M, GOUWY M, WANG J M, et al. Structure and expression of different serum amyloid A(SAA) variants and their concentration-dependent functions during host insults[J]. Curr Med Chem, 2016, 23(17):1725-1755. DOI URL
[3]	UHLAR C M, WHITEHEAD A S. Serum amyloid A,the major vertebrate acute-phase reactant[J]. Eur J Biochem, 1999, 265(2):501-523. DOI URL
[4]	陈长强, 顾志冬, 樊绮诗. 血清淀粉样蛋白A在疾病应用中的研究进展[J]. 检验医学, 2012, 27(9):776-779.
[5]	KLUVE-BECKERMAN B, YAMADA T, HARDWICK J, et al. Differential plasma clearance of murine acute-phase serum amyloid A proteins SAA1 and SAA2[J]. Biochem J, 1997, 322(Pt2):663-669. DOI URL
[6]	GRIFFITHS K, PAZDERSKA A, AHMED M, et al. Type 2 diabetes in young females results in increased serum amyloid a and changes to features of high density lipoproteins in both HDL₂,and HDL₃[J]. J Diabetes Res, 2017, 2017:1314864.
[7]	THOMPSON J C, WILSON P G, SHRIDAS P, et al. Serum amyloid A3 is pro-atherogenic[J]. Atherosclerosis, 2018, 268:32-35. DOI URL
[8]	AZURMENDI L, LAPIERREFETAUD V, SCHNEIDER J, et al. Proteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection:a pilot study[J]. Clin Proteomics, 2017, 14(1):27. DOI URL
[9]	THOMPSON J C, JAYNE C, THOMPSON J, et al. A brief elevation of serum amyloid A is sufficient to increase atherosclerosis[J]. J Lipid Res, 2015, 56(2):286-293. DOI URL
[10]	TAKASE H, FURUCHI H, TANAKA M, et al. Characterization of reconstituted high-density lipoprotein particles formed by lipid interactions with human serum amyloid A[J]. Biochim Biophys Acta, 2014, 1842:1467-1474.
[11]	HAN C Y, TANG C, GUEVARA M E, et al. Serum amyloid A impairs the anti-inflammatory properties of HDL[J]. J Clin Invest, 2016, 126(1):266-281. DOI URL
[12]	TOMITA T, IEGUCHI K, SAWAMURA T, et al. Human serum amyloid A3(SAA3) protein,expressed as a fusion protein with SAA2,binds the oxidized low density lipoprotein receptor[J]. PLoS One, 2015, 10(3):e0118835. DOI URL
[13]	陈振华, 蔡甜, 唐波, 等. 血清淀粉样蛋白A量子点免疫层析全血定量检测试剂的制备及性能评价[J]. 药物生物技术, 2018, 25(04):21-24.
[14]	姜剑巍, 杨宇, 应春妹. 乳胶增强免疫散射比浊法检测血清淀粉样蛋白A的应用评价[J]. 检验医学, 2015, 30(1):49-52.
[15]	陈长强, 杨晶, 顾志冬, 等. 斑点免疫金渗滤法定量测定血清淀粉样蛋白A方法的建立及性能评估[J]. 检验医学, 2013, 28(9):835-840.
[16]	李启欣, 梁指荣, 汤永平, 等. 血清淀粉样蛋白A免疫荧光层析法的建立[J]. 热带医学杂志, 2017, 17(9):1152-1155.
[17]	FLORES R J, KELLY A J, LI Y, et al. The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma[J]. Pediatric Blood Cancer, 2017, 64(12):e26659. DOI URL
[18]	田月如, 李巍, 叶志成, 等. 血清淀粉样蛋白A和C反应蛋白检测在儿童感染性疾病诊断中的应用[J]. 检验医学, 2017, 32(5):382-385.
[19]	AHOUT I M L, BRAND K H, ZOMER A, et al. Prospective observational study in two Dutch hospitals to assess the performance of inflammatory plasma markers to determine disease severity of viral respiratory tract infections in children[J]. BMJ Open, 2017, 7(6):e014596. DOI URL
[20]	李福刚, 雷蕾, 石晓强, 等. 血清淀粉样蛋白A(SAA)水平检测在临床实验诊断及健康监测中的应用[J]. 现代检验医学杂志, 2019,(3):1-5.
[21]	XIE X, MA Y T, YANG Y N, et al. Genetic polymorphisms of serum amyloid A1 and coronary artery disease risk[J]. Tissue Antigens, 2015, 85(3):168-176. DOI URL
[22]	VAISAR T, HIPPE D, NERADILEK M, et al. HDL-associated serum amyloid A(SAA) may be a predictor of cardiovascular risk independent of HDL- or LDL-cholesterol[J]. Atherosclerosis, 2017, 263:e218.
[23]	王旋, 程龙献, 崔天盆, 等. 血清淀粉样蛋白A与冠心病及冠心病危险因素的关系[J]. 临床心血管病杂志, 2004, 20(12):745-747.
[24]	JOHNSON B D, KIP K E, MARROQUIN O C, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women:the National Heart,Lung,and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation(WISE)[J]. Circulation, 2004, 109(6):726-732. DOI URL
[25]	ZHANG G, HARA H, YAMAMOTO T, et al. Serum amyloid a as an indicator of impending xenograft failure:experimental studies[J]. Int J Surg, 2018, 60:283-290. DOI URL
[26]	ZAIRIS M N, ADAMOPOULOU E N, MANOUSAKIS S J, et al. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes[J]. Atherosclerosis, 2007, 194(2):397-402. DOI URL
[27]	盛秀芝, 蔡溢, 周杰. 血清淀粉样蛋白A在肾移植术后排斥反应诊断中的价值[J]. 中国实验诊断学, 2010, 14(002):242-243.
[28]	WESTERMARK G T, FÄNDRICH M, WESTERMARK P. AA amyloidosis:pathogenesis and targeted therapy[J]. Annu Rev Pathol, 2015, 10:321-344. DOI URL
[29]	JAYARAMAN S, GANTZ D L, HAUPT C, et al. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis[J]. Proc Natl Acad Sci U S A, 2017, 114(32):E6507-E6515. DOI URL
[30]	余红梅, 周新, 彭志宇, 等. 血清淀粉样蛋白A1基因多态性与类风湿关节炎淀粉样变性的关系[J]. 新乡医学院学报, 2009, 26(1):46-49.
[31]	项国谦, 陈岳明, 冯迪英, 等. 血清淀粉样蛋白A在类风湿性关节炎中的临床价值[J]. 中国卫生检验杂志, 2016(20):2945-2946.
[32]	LIN H Y, TAN G Q, LIU Y, et al. The prognostic value of serum amyloid A in solid tumors:a meta-analysis[J]. Cancer Cell Int, 2019, 19(1):62. DOI URL
[33]	DJUREC M, GRAÑA O, LEE A, et al. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors[J]. Proc Natl Acad Sci U S A, 2018, 115(6):E1147-E1156. DOI URL
[34]	COOK M B, BARNETT M J, BOCK C H, et al. Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma:a study within the National Cancer Institute Cohort Consortium[J]. Gut, 2019, 68(6):960-968. DOI URL
[35]	ZHOU J, SHENG J, FAN Y, et al. Association between serum amyloid A levels and cancers:a systematic review and meta-analysis[J]. Postgrad Med J, 2018, 94(1115):499-507. DOI URL
[36]	NG C T, YIP G W C, CHEN E S, et al. Gold nanoparticles induce serum amyloid A 1-Toll-like receptor 2 mediated NF-κB signaling in lung cellsin vitro[J]. Chem Biol Interact, 2018, 289:81-89. DOI URL
[37]	RAMANKULOV A, LEIN M, JOHANNSEN M, et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma[J]. Cancer Lett, 2008, 269(1):85-92. DOI URL
[38]	罗健青, 陈秀芳, 管敏昌, 等. 血常规、C-反应蛋白联合血清淀粉样蛋白A水平早期检测在儿童流感中的应用价值[J]. 中国卫生检验杂志, 2019, 29(4):432-434.
[39]	张慧, 陈皓. 支原体肺炎患儿的血清淀粉样蛋白A及人软骨糖蛋白-39水平变化与及预后的相关性分析[J]. 中国儿童保健杂志, 2019, 27(3):314-316.
[40]	赵学芹, 梁绮华, 黄家良, 等. 血清淀粉样蛋白A与C反应蛋白在小儿手足口病早期诊断中的临床应用价值[J]. 国际检验医学杂志, 2015, 36(18):2699-2701.
[41]	LU W, CHEN B, WANG C, et al. Serum amyloid A levels in acute and chronic urticaria[J]. An Bras Dermatol, 2019, 94(4):411-415. DOI URL
[42]	孙娜, 冯冰瑜, 卢松科. C反应蛋白、血清淀粉样蛋白A联合Toll样受体蛋白4检测在儿童肾病中的表达变化及相关性研究[J]. 中国中西医结合肾病杂志, 2019, 20(5):421-423.
[43]	冯烨, 张宇, 周娟, 等. 血清淀粉样蛋白A水平在幼年特发性关节炎疾病活动度评估中的价值分析[J]. 第三军医大学学报, 2017, 39(19):1933-1938.